DIFFUSION PHARMACEUTICALS INC
Pagina dedicata companiei DIFFUSION PHARMACEUTICALS INC listata cu simbolurile US.DFFN, US.DFFNc
Descriere companieModificare
Diffusion Pharmaceuticals Inc. (www.diffusionpharma.com) is a biopharmaceutical company. The Company is engaged in the development of therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed. The Company’s product candidate includes Trans Sodium Crocetinate (TSC) and DFN-529. TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. Hypoxia is associated with the pathophysiology of many acute and chronic conditions including cancers, heart attack, stroke, ARDS, skin and soft tissue diseases, neurodegenerative diseases and other intractable and difficult-to-treat conditions, further complicating treatment of the underlying condition by medical providers. The Company completed the first of its three Oxygenation Trials (the TSC TCOM Trial) a Phase I trial. DFN-529, allosteric PI3K/Akt/mTOR pathway inhibitor, is in early-stage development. The Company previously completed two Phase I clinical trials of DFN-529.
Grafic actiuni companieModificare